ACCEL Lite: AHA Late-Breaker: DAPA-MI - A Registry-Based Randomized Trial of Dapagliflozin in Patients with Acute Myocardial Infarction Without Diabetes

This content requires a premium subscription.
Please log in or subscribe to continue.

Artwork for ACCEL Lite: AHA Late-Breaker: DAPA-MI - A Registry-Based Randomized Trial of Dapagliflozin in Patients with Acute Myocardial Infarction Without Diabetes

ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research